VVOSHealthcare · Medical DevicesThe 2 Wall Street analysts covering Vivos Therapeutics, Inc. hold a median 12-month price target of $1.93 — +1591.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Vivos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on VVOS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1591.6% from it.
Of the 16 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 June 2026 | Ascendiant Capital | Maintains | Buy | $3.00 → $3.10 |
| 22 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 17 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Apr 2026 | HC Wainwright& Co. | Maintains | Buy | — |
| 3 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 17 Nov 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 9 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 15 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 20 Nov 2024 | Ascendiant Capital | Reiterates | Buy | — |
| 19 Nov 2024 | Alliance Global Partners | Maintains | Buy | — |
| 20 Aug 2024 | Ascendiant Capital | Maintains | Buy | — |
| 17 Jan 2023 | Ascendiant Capital | Initiates | Buy | $2.50 |
| 13 Aug 2021 | Roth Capital | Maintains | Buy | $11 → $10 |
| 18 May 2021 | Roth Capital | Maintains | Buy | $12 → $11 |
| 11 Jan 2021 | Craig-Hallum | Initiates | Buy | — |
| 5 Jan 2021 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VVOS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Vivos Therapeutics, Inc. returned −95.6% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 92% of US stocks
Cheaper than 94% of US stocks
Cheaper than 67% of US stocks
Higher than 80% of US stocks
Higher than 69% of US stocks
Higher than 70% of US stocks
Higher than 14% of US stocks
Higher than 5% of US stocks
Higher than 1% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vivos Therapeutics, Inc. has a market value of $3.8M and an enterprise value of $14.1M.
Revenue in the twelve months to 30 June 2026: $20.9M. The latest quarter grew 34.9% year on year.
Net income over the same four quarters: −$25.6M, a −122.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$19.0M.
Trailing P/E: −0.1×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Vivos Therapeutics, Inc. employs 268 people — $78K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vivos Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Vivos Therapeutics said Nasdaq staff confirmed the company complies with Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity.
Why it matters — The confirmation provides VVOS watchers an update on the company’s compliance with Nasdaq’s continued listing equity standard.
Vivos Therapeutics said it closed an acquisition of a stake in SOD Sciences and a 50% interest in a pseudohypoxia test. The company said the transaction is expected to add more than $10 million to stockholders’ equity and that strategic alliances may create revenue and profit opportunities.
Why it matters — VVOS watchers may note the equity impact and potential access to more than 325,000 patients through the AHA channel described in the headline.
Vivos Therapeutics agreed to acquire a minority stake in SOD Sciences and a 50% interest in its proprietary pseudohypoxia test. The transaction is expected to increase stockholders’ equity and could open collaboration opportunities through new strategic alliances.
Why it matters — The agreement may expand Vivos’ strategic relationships and affect its stockholders’ equity.
Vivos Therapeutics announced that management is executing on a plan to reduce overhead by an estimated $3.6 million annually while also pursuing top-line revenue growth initiatives.
Why it matters — Cost reduction and revenue growth efforts could improve the company's financial position, which is relevant to investors tracking VVOS.
Vivos Therapeutics announced that on August 31, 2026, it entered into twelve exchange agreements with Streeterville Capital, LLC, converting $2,861,270 of outstanding principal under its secured promissory note into 11,445,080 shares of common stock at an exchange price of $0.25 per share.
Why it matters — This transaction reduces Vivos's outstanding debt under its secured promissory note, which could improve the company's balance sheet and financial flexibility.
The 2 Wall Street analysts covering Vivos Therapeutics, Inc. have a median 12-month price target of $1.93, with estimates ranging from $0.75 to $3.1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Vivos Therapeutics, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivos Therapeutics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Vivos Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +1591.6% from the last close, and Ticker Nerd's factor model ranks Vivos Therapeutics, Inc. 37 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vivos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VVOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.75 to $3.1 over the next 12 months.
Vivos Therapeutics, Inc. returned -95.6% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Vivos Therapeutics, Inc. is a medical technology and healthcare services company focused on addressing dentofacial abnormalities, obstructive sleep apnea, and snoring through non-invasive treatment solutions.
The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard". Vivos Therapeutics said Nasdaq staff confirmed the company complies with Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity.
Vivos Therapeutics, Inc. is a medical technology and healthcare services company focused on addressing dentofacial abnormalities, obstructive sleep apnea, and snoring through non-invasive treatment solutions. The company develops and commercializes the Vivos Method, an oral appliance-based approach used by trained dental and medical professionals to support airway health and sleep wellness. Its current offerings also include the VivoScore Program, which provides screening and home sleep testing for adults and children, along with related appliances, treatment protocols, and support services. Vivos Therapeutics works primarily with licensed professionals, especially general dentists, in the United States and Canada, positioning its products within the broader sleep-disordered breathing and oral appliance therapy markets. Based in Littleton, Colorado, the company serves as a specialized provider in the healthcare technology sector.
CEO Mr. R. Kirk Huntsman · 268 employees · United States · https://www.vivos.com
